Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.
3.

Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA.

Clin Ther. 2008 Aug;30(8):1524-39; discussion 1506-7. doi: 10.1016/j.clinthera.2008.08.009.

PMID:
18803994
4.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.

J Clin Psychiatry. 2004 Oct;65(10):1377-88.

PMID:
15491242
5.

Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.

Walthour A, Seymour L, Tackett R, Perri M.

Ann Pharmacother. 2010 May;44(5):809-18. doi: 10.1345/aph.1M620. Epub 2010 Apr 13.

PMID:
20388858
6.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

7.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
8.

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.

Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

J Manag Care Pharm. 2012 Nov-Dec;18(9):676-89.

9.

Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.

Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW.

Psychopharmacol Bull. 1998;34(3):373-82.

PMID:
9803771
11.

Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.

Baser O, Xie L, Pesa J, Durkin M.

J Med Econ. 2015 May;18(5):357-65. doi: 10.3111/13696998.2014.1001514. Epub 2015 Jan 19.

PMID:
25525771
13.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
14.

Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006.

Alessi-Severini S, Biscontri RG, Collins DM, Kozyrskyj A, Sareen J, Enns MW.

Psychiatr Serv. 2008 May;59(5):547-53. doi: 10.1176/ps.2008.59.5.547.

PMID:
18451015
15.

Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.

He X, Wu J, Jiang Y, Liu L, Ye W, Xue H, Montgomery W.

BMC Health Serv Res. 2015 Apr 9;15:149. doi: 10.1186/s12913-015-0819-y.

16.

Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.

Seabury SA, Goldman DP, Kalsekar I, Sheehan JJ, Laubmeier K, Lakdawalla DN.

Am J Manag Care. 2014 Feb 1;20(2):e52-60.

17.

Use of conventional antipsychotics and the cost of treating schizophrenia.

Lyu RR, McCombs JS, Johnstone BM, Muse DN.

Health Care Financ Rev. 2001 Winter;23(2):83-99.

18.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
19.

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV.

Am J Psychiatry. 2004 Apr;161(4):692-9.

PMID:
15056516

Supplemental Content

Support Center